Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Recipient : Breye Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to develop the P2X7 receptor antagonist programme. Orally available antagonists of the P2X7 receptor represent a novel approach for the treatment of both early-stage DR and dry-AMD.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 25, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : Breye Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
